Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

2003-10-01

Annals of Hematology , Volume 82 - Issue 10 p. 654- 659

Additional Metadata
Persistent URL	doi.org/10.1007/s00277-003-0685-2, hdl.handle.net/1765/53122
Journal	Annals of Hematology
Organisation	Department of Hematology
Citation APA APA Style APA-ALL Style AAA Style Cell Style Chicago Style Harvard Style IEEE Style MLA Style Nature Style Vancouver Style American-Institute-of-Physics Style Council-of-Science-Editors Style BibTex Format Endnote Format RIS Format CSL Format DOIs only Format	Goldschmidt, H., Martin, H., Hoelzer, D., Ho, A., Lokhorst, H., Sonneveld, P., Cremer, F. W., van der Holt, B., Westveer, P., Breitkreutz, I., Benner, A., Glasmacher, A.& Schmidt-Wolf, I. G. H. (2003). Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Annals of Hematology, 82(10), 654–659.https://doi.org/10.1007/s00277-003-0685-2

Publication